{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-26-002338","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.755239+00:00","generated_at":"2026-05-15T10:10:39.669655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Pharma-Bio Serv Q1 revenue $2.3M, net income $32,860","bullets":["Revenue of approx. $2.3M, down ~$0.2M from prior year quarter.","Net income of $32,860, an improvement of $24,324 compared to net loss in same quarter last year.","CEO cites improved operational efficiency and disciplined cost management.","Company focuses on sharpening service portfolio and concentrating on highest-value markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-002338","json":"https://secwatch.observer/filing/0001654954-26-002338.json","markdown":"https://secwatch.observer/filing/0001654954-26-002338.md","text":"https://secwatch.observer/filing/0001654954-26-002338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/0001654954-26-002338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:10:39.669655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cc3440f14b3cff757094d35c27de96336285611","claim":"Pharma-Bio Serv, Inc. reported quarter ended January 31, 2026 results: revenue approximately $2.3 million, net income $32,860.","evidence_excerpt":"biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/0001654954-26-002338-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended January 31, 2026"},{"label":"Revenue","value":"approximately $2.3 million"},{"label":"Net income","value":"$32,860"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}